Clearance of therapy‐induced senescent tumor cells by the senolytic ABT‐263 via interference with BCL‐XL–BAX interaction
Tumor cells undergo senescence in response to both conventional and targeted cancer therapies. The induction of senescence in response to cancer therapy can contribute to unfavorable patient outcomes, potentially including disease relapse. This possibiliy is supported by our findings that tumor cell...
Main Authors: | Tareq Saleh, Valerie J. Carpenter, Liliya Tyutyunyk‐Massey, Graeme Murray, Joel D. Leverson, Andrew J. Souers, Moureq R. Alotaibi, Anthony C. Faber, Jason Reed, Hisashi Harada, David A. Gewirtz |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-10-01
|
Series: | Molecular Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1002/1878-0261.12761 |
Similar Items
-
EA.hy926 Cells and HUVECs Share Similar Senescence Phenotypes but Respond Differently to the Senolytic Drug ABT-263
by: Ibrahim Y. Abdelgawad, et al.
Published: (2022-06-01) -
Bcl-XL but Not Bcl-2 Is a Potential Target in Medulloblastoma Therapy
by: Mike-Andrew Westhoff, et al.
Published: (2022-01-01) -
Clearance of senescent cells with ABT-263 improves biological functions of synovial mesenchymal stem cells from osteoarthritis patients
by: Yugo Miura, et al.
Published: (2022-06-01) -
Effects of senolytic drugs on human mesenchymal stromal cells
by: Clara Grezella, et al.
Published: (2018-04-01) -
ABT-263 Reduces Hypertrophic Scars by Targeting Apoptosis of Myofibroblasts
by: Xiaolan Yang, et al.
Published: (2021-01-01)